Home » SciClone, Sigma-Tau Report Positive Results From Influenza Vaccine Trial
SciClone, Sigma-Tau Report Positive Results From Influenza Vaccine Trial
SciClone Pharmaceuticals and its partner Sigma-Tau have received
initial topline results in a clinical study valuating the potential of Zadaxin to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent
vaccine, Focetria from Novartis.
Trading Markets
Trading Markets
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May